DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of DBV Technologies in a research report on Wednesday, February 21st.

DBV Technologies Trading Down 2.7 %

Shares of DBVT stock opened at $0.70 on Friday. The business’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.91. The company has a market cap of $135.01 million, a PE ratio of -1.79 and a beta of 0.75. DBV Technologies has a 12-month low of $0.65 and a 12-month high of $2.37.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million for the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same period in the prior year, the firm posted ($0.23) earnings per share. On average, equities analysts forecast that DBV Technologies will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently made changes to their positions in DBVT. Point72 Asset Management L.P. acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $5,914,000. Millennium Management LLC increased its position in shares of DBV Technologies by 53.9% in the 4th quarter. Millennium Management LLC now owns 871,996 shares of the company’s stock valued at $1,334,000 after acquiring an additional 305,562 shares during the period. Optiver Holding B.V. increased its position in shares of DBV Technologies by 595.2% in the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after acquiring an additional 235,337 shares during the period. ExodusPoint Capital Management LP acquired a new position in shares of DBV Technologies in the 2nd quarter valued at $352,000. Finally, BlackRock Inc. increased its position in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock valued at $1,093,000 after acquiring an additional 97,412 shares during the period. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.